🇺🇸 FDA

Company profile · Sponsor

Bial

Bial Portela & Companhia S.A.

ED9AD99 · EMA pharma EU
Pipeline
6
Drugs
0
Patents
0

Quick answer

Bial (ED9AD99) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker ED9AD99
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (6)

Search pipeline →

  1. GLUCOPHAGE 500 mg tabletki powlekane, Placebo

    Bial

    papillary thyroid carcinoma

    phase 3 small molecule active

    1 trial

  2. PSMA-11 kit for Ga-68 labelling

    Bial

    Intermediate and high-risk prostate cancer

    phase 3 small molecule active

    1 trial

  3. Placebo, Atoris, 40 mg, tabletki powlekane

    Bial

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  4. Placebo, Minirin, 4 mikrogramy/ml, roztwór do wstrzykiwań

    Bial

    Rare and ultra-rare glomerulonephritis

    phase 3 small molecule active

    1 trial

  5. Placebo, GLUCOPHAGE 500 mg tabletki powlekane

    Bial

    idiopathic infertility

    phase 2 small molecule active

    1 trial

  6. Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment

    Bial

    Parkinson's disease

    phase 1 other active

    1 trial

Frequently asked questions

What is Bial?

Bial (ED9AD99) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Bial sponsor?

We track 6 ClinicalTrials.gov-linked programs for Bial, including GLUCOPHAGE 500 mg tabletki powlekane, Placebo and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Bial company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.